XORTX Therapeutics Inc. Overview
Pro stress-test →XORTX Therapeutics is a late-stage clinical pharmaceutical company specializing in treatments for gout and progressive kidney disease. The company's lead asset, XORLO™, is being advanced for allopurinol-intolerant gout with the company preparing for commercialization and guiding to an NDA filing in 2026. The company aims to address significant unmet needs in gout and rare kidney disorders.
Strategic Profile
Pro stress-test →XORTX's updated clinical plan includes a two-part bridging study, XRX-OXY-102, to assess pharmacokinetics and therapeutic equivalence versus allopurinol, targeting a roughly $700 million-per-year gout market. The company's value proposition was strengthened by the acquisition of the VB4-P5 renal anti-fibrotic program in October 2025, a patent-protected small-molecule therapy that has demonstrated compelling preclinical activity in models of kidney fibrosis.
Competitive Landscape
Pro stress-test →XORTX's lead gout candidate is positioned via FDA 505(b)(2) pathway, which offers reduced development risk, lower cost, and shorter timelines to market. The company competes in niche therapeutic areas focused on purine metabolism and xanthine oxidase inhibition, targeting orphan kidney indications (ADPKD) and allopurinol-intolerant gout populations with limited approved treatment options.
Industry Context
XORTX Therapeutics Inc. operates in Specialty pharmaceuticals for gout and progressive kidney disease.
Key facts
Founded: N/A · Headquarters: Calgary, Canada · Employees: N/A · Revenue: N/A · Market cap: N/A